Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease.
Patients with cancer and suspected sepsis were treated in a prospective, randomized trial with one of four cephalosporin-aminoglycoside combinations: cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; or cefamandole and gentamicin. Carbenicillin was added if the absolute granulocyte count was less than 1,000/mm3. Of 199 patients receiving 20 to more doses of an aminoglycoside and having serial determination of serum creatinines, nephrotoxicity developed in seven (3.5%) given any of the four combinations. There were no significant differences between patients receiving either cephalosporin or either aminoglycoside. Nephrotoxicity developed less frequently among children (2 or 125; 1.6%) than adults (5 of 74; 6.8%).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000617:Aminoglycosides / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002511:Cephalosporins / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D006801:Humans; D007223:Infant; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations